what is glp 1 agonist drugs Top GLP-1 Agonists Balance Weight Loss Efficacy, Safety Table 3 from Glucagon-Like Peptide-1

Brain Inj

Weight Loss: Average weight loss in the LEAD trials was 2 kg to 3.24 kg, with the majority of the reduction noted in the first 4 months of therapy, but tending to be sustained throughout the remaining period of the studies

Increased lipase and alanine aminotransferase were noted in 3 (23.1%) and 1 (7.7%) of the patients, respectively, with none of those resulting in pancreatitis and/or cholelithiasis

In the T2D trial, WL was lower than in the obesity trial however the trial duration was shorter (36 weeks) [46]

[DOI] [PubMed] [Google Scholar] 488.Doyle M.E., Egan J.M

Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease